In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardica: Rebuilding the Cardiac Surgery Market

Executive Summary

The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.

You may also be interested in...



Estech: Back From the Brink

Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.

Estech: Back From the Brink

Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.

Challenges & Opportunities for CABG Surgery

Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel